Efficacy evaluation of antidepressant drugs utilized at tertiary care centre in North Karnataka in psychiatric outpatient department

Harish G. Bagewadi¹, Chandrashekar B. Huded²*

ABSTRACT

Background: Depression is the major psychotic disorder affecting 9.5% of population worldwide. Present study investigates the prescribing patterns of different antidepressants evaluating their efficacy.

Methods: This was a prospective, observational study which was conducted in the out-patient department of Psychiatry and Pharmacology in Gulbarga Institute of Medical Sciences, Kalaburagi. A total of 200 cases were enrolled for the present study. Statistical analysis for efficacy was done using Wilcoxon’s signed rank test.

Results: Predominantly, females suffered from depression when compared to male counterparts. In our study, monotherapy was practiced more frequently than polytherapy with 2 or more drugs. Selective serotonin reuptake inhibitors (SSRIs) like Escitalopram was found out to be the most widely used antidepressant drug.

Conclusions: Among antidepressant medications, SSRIs are preferred over others because of their better side effect profile.

Keywords: Depression, Antidepressant, Monotherapy

INTRODUCTION

Depression is a major important global public health problem due to present days lifestyle modifications, under preparedness to life situations.¹ Depression can be defined as a mental state which is characterized by feelings of sadness, low self-esteem, loneliness and despair. These are also combined with psychomotor retardation or at times, social withdrawal from interpersonal contact.² The physical symptoms of depression which can be presented are- fatigue and reduced activity, unexplained aches, disturbed sleep or excessive sleep, changes in appetite and weight, and loss of sex drive.³ Depression accounted ascending score of for 4.46% of the total DALYs (disability adjusted life years) and 12.1% of the YLDs (years lived with disability) in 2002, when compared to 3.7% of the DALYs and 10.7% of the YLDs in 1990.⁴ A drug utilization study is planned to evaluate the prescribing, dispensing, administration of antidepressant medications. They also give an idea of near approximation of the disease prevalence to plan drug production and procurement. Many studies have pointed to significant changes in the prescribing habits of antidepressants.⁵ Thus, it is important to know the current prescribing habits of antidepressant medications.
There are few studies in the literature which highlights on the prescribing patterns of different antidepressant medications and evaluating their efficacy. Thus, it is important to know the current trend of drug usage and the effectiveness of the drugs which are used for depression. Present study investigates the prescribing patterns of different antidepressants and evaluating their efficacy by Hamilton rating scale for depression (HRSD).

**METHODS**

The present study is a prospective, observational and cross sectional clinical study. Subjects were selected from patients who presented to the O.P.D. of Department of Psychiatry of Gulbarga Institute of Medical Sciences, Kalaburagi. The study was done over a period of 6 months from September-2018 to February 2019. The 200 numbers of subjects were included in the study. A prescribed proforma was prepared by the study team to collect and record the data. Institutional ethics committee permission was taken prior to the study. Informed consent was taken prior to patient’s inclusion into the study.

**Inclusion criteria**

Inclusion criteria were outdoor patients suffering from depressive disorder attending O.P.D. of Department of Psychiatry; patients from all age groups and both the sexes are included; pregnant ladies suffering depressive disorders; understood the purpose of study and were ready to provide information regarding their health status and signed an informed consent document.

**Exclusion criteria**

Exclusion criteria were patients suffering from malignancies and terminally ill patients; were judged clinically to be at suicidal risk (too serious to be included in the study); had a history of allergic or serious adverse reactions to study the medications; had history of substance abuse. The following data were collected on the prescribed proforma to study the incidence, prevalence and risk factors associated with depression in our study population. All the above data of 200 patients were tabulated and put into Chi-Square test to study level of significance in the causation of depression. Antidepressant medication history is received by the subjects i.e. drug doses and frequency of the drugs, type of disease, strength of antidepressant, the duration of the treatment, etc. in the prescribed proforma. The Antidepressants were divided into three groups: Group 1 (TCAs), Group 2 (SSRIs) & Group 3 (SNRIs). Thereby, the pattern of anti-depressant drugs used in different subsets of population was analyzed. Those subjects on TCAs or on SSRIs or on newer antidepressants (SNRIs) were subjected to detailed neuro-psychiatric examination at the point of entry into the study and were subsequently followed up at three and six months to assess the efficacy of each drug. Efficacy was assessed under the domain of psychopathology and was quantitatively evaluated by using the HDRS scale (17 items, 0-4 severity scale). The analysis of HDRS score was done statistically at baseline and at the end of 3 months and 6 months.

The HRSD, also known as the Hamilton depression rating scale (HDRS) or abbreviated to HAM-D, constitutes the multiple choice questionnaire that physicians may use to rate the severity of a patient's major depression. Each question has 3-5 possible response items which increase in severity. A score of 0-7 is considered to be normal, scores of 20 or more points towards severe depression and are usually required for entry into a clinical trial. Questions 18-21 may be recorded to give further information about the depression (such as whether diurnal variation or paranoid symptoms are present), but are not part of the scale. Although Hamilton's original scale had 17 questions, others later developed HDRS scales with different numbers of questions; the greatest of which is 29 (HRSD-29).

**Statistical analysis**

For the analysis of demographic profile data Chi square test and for efficacy evaluation Wilcoxon’s signed rank test were used, with a p value of less than 0.05, with statistically significant.

**RESULTS**

In our study, it was observed in (Table 1) that majority of study participants were middle aged adults within the age group of 36-50 years (73%) followed by age group 51-64 years (53%). Prevalence of depression is more in females (112) i.e. 56% than males (88) i.e. 44%. In our study, it was evident that the average age of onset of depression was 49.2 years (Table 1) and the average length of duration of illness was 2.6 years.

<table>
<thead>
<tr>
<th>Sex of patient</th>
<th>Items</th>
<th>Age (in years)</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>0-17</td>
<td>18-35</td>
</tr>
<tr>
<td>Male</td>
<td>Count</td>
<td>14</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>% within sex of patient</td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td></td>
<td>% within age of onset</td>
<td>58.33</td>
<td>45.6</td>
</tr>
<tr>
<td>Female</td>
<td>Count</td>
<td>08</td>
<td>20</td>
</tr>
<tr>
<td></td>
<td>% within sex of patient</td>
<td>4</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>% within age of onset</td>
<td>41.66</td>
<td>54.83</td>
</tr>
</tbody>
</table>

Continued.
indicating the 41.40% of improvement. In the 3
1st visit. After 6 months there was marked 53.7%
improvement with SSRIs treated group. In the
TCA treated group showed baseline score of 28.5 after 1st visit. In the 3rd visit, after 6 months there was marked 50.01% improvement with SNRIs treated group. In the newer SNRI treated group, showed baseline score of 28.8 after 1st visit. After 3 months in the second visit HDRS score decreased to 15.4, indicating the 41.40% of improvement. In the 3rd visit, after 6 months there was marked 51.6% improvement with SSRIs plus SNRI treated group. In the TCA treated group, showed baseline score of 28.5 after 1st visit. In the 3rd visit, after 6 months there was marked 48.7% improvement with SSRIs plus SNRI treated group. In the newer SNRI treated group, showed baseline score of 28.8 after 1st visit. After 3 months in the second visit HDRS score decreased to 15.7, indicating the 40.05% of improvement. In the 3rd visit, after 6 months there was marked 53.7% improvement with SNRIs treated group.

DISCUSSION
Antidepressants were prescribed more in females than in males. Prevalence of depression is more in females (112) i.e. 56% than males (88) i.e. 44%. This was consistent with the findings of other studies. The age distribution shows that the majority of patients who received the antidepressants belonged to the 21-40 years age group, in contrast to the results of a study on antidepressant use in East Asia, wherein the mean age of the patients who received antidepressant prescriptions was more than 40 years. Our study finding of 73% of the patients are over 40 years, is also the same with previous studies conducted by Uchida et al.17
In another study in Europe, where antidepressants were the second most commonly prescribed psychotropic drugs, a majority of the users were between 35 and 49 years, with a mean age which was greater than 40 years. In our study, it was observed that monotherapy with different group of antidepressant medication was practiced in 156 patients i.e. 78% of the study population. In only 54 patients i.e. 28%, polytherapy with 2 drugs of different group antidepressant medication was prescribed. Polytherapy includes combination of SSRI, TCA and newer group of antidepressants. Our study findings are similar with previous studies done by Chaturvedi et al.

Majority of patients were prescribed antidepressant drugs from 3 different categories or different compounds from same category. Other studies too consistently found polypharmacy like our study where polypharmacy is about 28%. It is difficult to treat cases like treatment resistant schizophrenia or depression, mixed diagnosis and double diagnosis, drug combination is needed. But there is a lack of evidence based strategies to guide this practice. In our study 61.5% of the prescriptions were having polypharmacy and is in line with that of conducted by Cuevas and Mortimer who found that incidence of polypharmacy was 41.9% and 100% respectively. It is observed in our study that, the most frequently prescribed antidepressant was escitalopram (13.5%) and the most frequently prescribed newer antidepressant was duloxetine (9%). The most frequently prescribed combination therapy was that of Fluoxetine plus Amitriptyline (06%) in the study population. The most commonly prescribed antidepressant drug in our study was escitalopram (16.5%) followed by fluoxetine as monotherapy (15%) both belonging to the group ssri as monotherapy. These study findings are in associations with previous studies done by Lahon et al.

Hamilton depression rating scale (HDRS score) was used to evaluate the efficacy assessment of antidepressants. Out of all the patients treated, 102 were on SSRI, 33 patients were on TCA & 57 were on newer combinations (SNRI). Among patients on SSRIs, there were significantly lower HDRS scores both at the end of 3 months and 6th month compared to initials HDRS score. When HDRS scores of 2nd and 3rd visit of same group (SSRI) were compared, it was found that 59 cases had lower HDRS scores on third visit than second, while the rest 13 cases had equal HDRS scores on both second and third visits (Table 4). Based on our observations, it is evident that, SSRI groups of antidepressants show maximal beneficial effect after third month.

All the 33 patients on TCA’s had reduced HDRS scores at end of 3rd month and 6th month. However, when HDRS scores of 2nd and 3rd visits were compared, it was found that 19 cases had less HDRS scores on 3rd visit than 2nd compared to baseline score, and in rest 14 cases, there were equal HDRS scores. Based on our observations, it is evident that in contrast to SSRI group, patients on TCA’s have maximal benefit early i.e. (end of 3rd month). In the newer antidepressant group containing 57 patients on SNRIs, all 57 of them had reduced HDRS scores on second visit (3 months). While 55 had reduced HDRS scores on the third visit (6 months) on comparison to second visit (3 months), only 2 cases had equal HDRS scores on both the visits. At the end of 3rd month, it was observed that the percentage of improvement in TCA’S is almost equal with the other two groups of drugs prescribed; i.e. SSRI and newer antidepressants and the percentage of improvement of all the group of drugs at 6 months was comparable i.e. SSRIs -51.6%, TCAs -50.1%, and newer antidepressants – 53.7% respectively. This shows that there is a little difference among the three treatment groups in percentage of improvement of symptoms after three months of treatment. However, after 6 months, the percentage of improvement was 52% for SSRI, 51% for TCA and 53% for newer groups. Our study findings are in accordance with previous study done by Mishra et al and Deshmukh et al. Our study limitations were- our results should however be seen in the light of our small sample size, as compared to the studies with which they have been compared. The limitations of this study were the lack of patient care indicators and some of the facility indicators like the availability of drugs and the impact of cost on the drug treatment, which can increase the utility of the study. Still, many studies are required to assess the efficacy evaluation of antidepressant drugs to benefit the patients.

CONCLUSION

Females suffer from depression more when compared to their male counterparts. Monotherapy is practiced more frequently than polytherapy and conventional drugs like SSRIs are more preferred than newer antidepressants in our institution.

Funding: No funding sources
Conflict of interest: None declared
Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES


Cite this article as: Bagewadi HG, Huded CB. Efficacy evaluation of antidepressant drugs utilized at tertiary care centre in North Karnataka in psychiatric outpatient department. Int J Basic Clin Pharmacol 2019;8:2465-9.